A Phase 2 interventional study of ALN-PCSSC and Standard of Care in Homozygous Familial Hypercholesterolemia, sponsored by The Medicines Company. Completed at 3 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-05-18.
Sponsored by The Medicines Company (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States — 7 open to participants now, 9 under way, 4 of them phase 3. Homozygous Familial Hypercholesterolemia · United States.
Among the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, this one is the 25th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2016, is one of 8 in phase 2, and was the 17th registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →7 of the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Wisconsin, Madison · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
CRISPR Therapeutics AG · Sites in United States, Australia, New Zealand and 1 more country
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Argentina, Brazil and 23 more countries
Ages 2–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 18
First in 2003; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 29 across the 31 interventional studies, 60 across the 5 observational. Of the 26 that completed or were terminated, 19 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under The Medicines Company, one of the names counted as Novartis. Under that name alone:
The Medicines Company is the lead sponsor of 50 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Novartis has 7 studies filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Homozygous Familial Hypercholesterolemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07037771Phase 3Arrowhead PharmaceuticalsA Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | 2027-08-20 |
| NCT04815005University of PennsylvaniaHoFH, the International Clinical Collaborators Registry | 2026-12-31 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by \>70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
Drug: ALN-PCSSC · Drug: Standard of Care
ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
Also known as: PCSK9 synthesis inhibitor
Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
Percentage Change From Day 1 to Day 90 in LDL-C
Due to the small number of subjects, and the fact that the data are not normally distributed, the data are presented as descriptive statistics with no inferential and limited summary statistics presented.
Time frame: Day 1, Day 90
Percentage Change From Day 1 to Day 180 (or Final Visit) in LDL-C
Time frame: Day 1, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in LDL-C
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 60 and to Day 90 in PCSK9
Time frame: Day 1, Day 60, Day 90
Absolute Change From Day 1 to Day 60 and to Day 90 in PCSK9
Time frame: Day 1, Day 60, Day 90
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Total Cholesterol
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Triglycerides
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in HDL-C
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Non-HDL-C
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in VLDL-C
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein A1
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Apolipoprotein B
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Percentage Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a
The reported percent change value is the per participant calculated Mean.
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
Absolute Change From Day 1 to Day 90 and to Day 180 (or Final Visit) in Lipoprotein-a
Time frame: Day 1, Day 90, Day 180 (or Final Visit)
| Milestone | Inclisiran |
|---|---|
| Started | 9 |
| Completed | 4 |
| Not completed | 5 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Screen failure | 4 |
Due to the small number of subjects, and the fact that the data are not normally distributed, the data are presented as descriptive statistics with no inferential and limited summary statistics presented.
| percent change | Inclisiran |
|---|---|
| Percentage Change From Day 1 to Day 90 in LDL-C | -12.26 (-43.75 to 19.24) |
| percent change | Inclisiran |
|---|---|
| Percentage Change From Day 1 to Day 180 (or Final Visit) in LDL-C | -20.96 (-49.97 to 8.05) |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -56.3 ± 115.18 |
| Day 180 | -105.3 ± 116.44 |
| percent change | Inclisiran |
|---|---|
| Day 60 | -64.9 ± 18.33 |
| Day 90 | -59.0 ± 16.46 |
| ng/mL | Inclisiran |
|---|---|
| Day 60 | -654.1 ± 564.67 |
| Day 90 | -602.3 ± 559.61 |
| percent change | Inclisiran |
|---|---|
| Day 90 | -13.9 ± 14.84 |
| Day 180 | -19.8 ± 13.68 |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -77.8 ± 103.41 |
| Day 180 | -118.0 ± 103.52 |
| percent change | Inclisiran |
|---|---|
| Day 90 | -21.0 ± 30.99 |
| Day 180 | -20.13 ± 11.67 |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -35.5 ± 38.76 |
| Day 180 | -26.3 ± 24.64 |
| percent change | Inclisiran |
|---|---|
| Day 90 | -12.1 ± 17.98 |
| Day 180 | -19.8 ± 11.78 |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -6.0 ± 9.13 |
| Day 180 | -9.5 ± 4.73 |
| percent change | Inclisiran |
|---|---|
| Day 90 | -13.9 ± 14.78 |
| Day 180 | -19.7 ± 13.93 |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -71.8 ± 97.70 |
| Day 180 | -108.5 ± 99.38 |
| percent change | Inclisiran |
|---|---|
| Day 90 | 8.5 ± 65.28 |
| Day 180 | 55.5 ± 131.92 |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -15.5 ± 28.41 |
| Day 180 | -3.3 ± 37.32 |
| percent change | Inclisiran |
|---|---|
| Day 90 | -8.3 ± 12.95 |
| Day 180 | -14.2 ± 14.44 |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -11.5 ± 17.52 |
| Day 180 | -19.8 ± 19.00 |
| percent change | Inclisiran |
|---|---|
| Day 90 | -26.6 ± 14.98 |
| Day 180 | -25.0 ± 14.50 |
| mg/dL | Inclisiran |
|---|---|
| Day 90 | -95.3 ± 78.16 |
| Day 180 | -86.3 ± 72.02 |
The reported percent change value is the per participant calculated Mean.
| percent change | Inclisiran |
|---|---|
| Day 90 | -3.5 ± 15.70 |
| Day 180 | -11.8 ± 15.15 |
| nmol/L | Inclisiran |
|---|---|
| Day 90 | 13.5 ± 21.92 |
| Day 180 | -23.8 ± 52.73 |
Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Event | Inclisiran |
|---|---|
| Angina unstableCardiac disorders | 1/4 |
| Event | Inclisiran |
|---|---|
| Angina unstableCardiac disorders | 1/4 |
| Abdominal pain upperGastrointestinal disorders | 1/4 |
| Influenza like illnessGeneral disorders | 1/4 |
| Non-cardiac chest painGeneral disorders | 1/4 |
| CystitisInfections and infestations | 1/4 |
| NasopharyngitisInfections and infestations | 1/4 |
| Limb injuryInjury, poisoning and procedural complications | 1/4 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/4 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/4 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/4 |
| Age, Categorical(Participants) | Inclisiran |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 0 |
| Age, Continuous(years) | Inclisiran |
|---|---|
| Mean | 37.0 ± 13.04 |
| Sex: Female, Male(Participants) | Inclisiran |
|---|---|
| Female | 2 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Inclisiran |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Inclisiran |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Inclisiran |
|---|---|
| Netherlands | 1 |
| South Africa | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Oct 2018, 21 months.
Results were first posted in May 2020, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran
Homozygous Familial Hypercholesterolemia →